NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis $23.10 -0.20 (-0.86%) Closing price 04:00 PM EasternExtended Trading$22.52 -0.58 (-2.53%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Neurogene Stock (NASDAQ:NGNE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neurogene alerts:Sign Up Key Stats Today's Range$22.21▼$23.3850-Day Range$21.56▼$37.8852-Week Range$15.93▼$43.66Volume278,143 shsAverage Volume294,110 shsMarket Capitalization$478.17 millionP/E RatioN/ADividend YieldN/APrice Target$79.57Consensus RatingBuy Company Overview Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases. Founded in 2018, Neurogene is based in the United States and is led by founder and Chief Executive Officer Rachel McMinn.AI Generated. May Contain Errors. Read More Neurogene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreNGNE MarketRank™: 2.35415009281 of 5 starsNeurogene scored higher than 47% of companies evaluated by MarketBeat, and ranked 574th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNeurogene has a consensus price target of $79.57, representing about 244.5% upside from its current price of $23.10.Amount of Analyst CoverageNeurogene has only been the subject of 4 research reports in the past 90 days.Read more about Neurogene's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Neurogene are expected to decrease in the coming year, from ($5.26) to ($5.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurogene is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurogene is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.17% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 16.95, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 11.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.67 News SentimentNeurogene has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Neurogene this week, compared to 3 articles on an average week.Search Interest2 people have searched for NGNE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Neurogene to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have not sold or bought any company stock.Percentage Held by Insiders11.68% of the stock of Neurogene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGNE Stock News HeadlinesNeurogene FY2026 Earnings Forecast Raised by HC WainwrightNovember 14 at 2:27 AM | americanbankingnews.comCanaccord Genuity Keeps Their Buy Rating on Neurogene (NGNE)November 12, 2026 | theglobeandmail.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 17 at 1:00 AM | Behind the Markets (Ad)HC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock PriceNovember 12, 2026 | americanbankingnews.comNeurogene Inc. (NGNE) Latest Stock News & Headlines - Yahoo FinanceNovember 10, 2026 | finance.yahoo.comNeurogene Reports Third Quarter 2026 Financial Results and Highlights Recent UpdatesNovember 9, 2026 | businesswire.comNeurogene to Participate in Upcoming Investor ConferencesNovember 3, 2026 | businesswire.comNeurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett SyndromeOctober 27, 2026 | businesswire.comSee More Headlines NGNE Stock Analysis - Frequently Asked Questions How have NGNE shares performed this year? Neurogene's stock was trading at $20.60 at the start of the year. Since then, NGNE stock has increased by 12.1% and is now trading at $23.10. How were Neurogene's earnings last quarter? Neurogene Inc. (NASDAQ:NGNE) released its earnings results on Monday, November, 9th. The company reported ($1.05) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.31. When did Neurogene IPO? Neurogene (NGNE) raised $46 million in an IPO on Thursday, March 6th 2014. The company issued 4,200,000 shares at $10.00-$12.00 per share. Who are Neurogene's major shareholders? Top institutional shareholders of Neurogene include Samsara Biocapital LLC (9.02%), State Street Corp (2.65%), Great Point Partners LLC (1.45%) and Integral Health Asset Management LLC (0.97%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Rachel Mcminn, Christine Mikail Cvijic and Stuart Cobb. View institutional ownership trends. How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/09/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 6 days, NGNE's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees131Year Founded2018Price Target and Rating Average Price Target for Neurogene$79.57 High Price Target$166.00 Low Price Target$50.00 Potential Upside/Downside+244.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($5.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-44.36% Return on Assets-40.61% Debt Debt-to-Equity RatioN/A Current Ratio19.97 Quick Ratio10.64 Sales & Book Value Annual Sales$930 thousand Price / Sales514.16 Cash FlowN/A Price / Cash FlowN/A Book Value$17.14 per share Price / Book1.35Miscellaneous Outstanding Shares20,700,000Free Float18,283,000Market Cap$478.17 million OptionableOptionable Beta1.75 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:NGNE) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.